Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside in Heart Failure
NCT04528004Phase 1Active, not recruiting
- Sponsor
- University of Washington
- Start
- Sep 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF) comparing Nicotinamide riboside with Placebo (2 arms). Primary endpoint: Whole blood NAD+ levels up to 14 days. Started Sep 2020; status: active, not recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04528004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528004.